Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

CENTRAL NERVOUS SYSTEM EFFECTS OF THALIDOMIDE

W. L. Kuhn and E. F. Van Maanen
Journal of Pharmacology and Experimental Therapeutics October 1961, 134 (1) 60-68;
W. L. Kuhn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. F. Van Maanen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In animals the pharmacological action of thalidomide is not characteristic of the usual hypnotic agents since it does not produce loss of righting reflexes or respiratory depression. Central nervous system depression produced by thalidomide can be demonstrated by its effect on spontaneous motor activity, potentiation of central depressants, and antagonism of central stimulants.

In contrast to the barbiturates, thalidomide produces a decrease in motor activity of mice in doses which do not alter motor coordination. Furthermore, it does not produce hyperactivity in low doses.

Thalidomide antagonizes the hyperactivity induced in mice by caffeine and pipradrol but is less effective against the stimulant action of d-amphetamine.

Thalidomide potentiates and prolongs the central nervous system effects of hexobarbital and barbital sodium. In some instances the potentiating effect of thalidomide is specific for certain drug actions. Thus, it potentiates the effect of anticonvulsants on maximal electroshock seizures but does not alter the acute toxicity of these drugs. It potentiates the central nervous system depressant action of chlorpromazine but does not alter significantly the dose of chlorpromazine which blocks the conditioned avoidance response.

Footnotes

    • Received March 30, 1961.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 134, Issue 1
1 Oct 1961
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CENTRAL NERVOUS SYSTEM EFFECTS OF THALIDOMIDE
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CENTRAL NERVOUS SYSTEM EFFECTS OF THALIDOMIDE

W. L. Kuhn and E. F. Van Maanen
Journal of Pharmacology and Experimental Therapeutics October 1, 1961, 134 (1) 60-68;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

CENTRAL NERVOUS SYSTEM EFFECTS OF THALIDOMIDE

W. L. Kuhn and E. F. Van Maanen
Journal of Pharmacology and Experimental Therapeutics October 1, 1961, 134 (1) 60-68;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Differential Effects of Mibefradil, Verapamil, and Amlodipine on Myocardial Function and Intracellular Ca2+ Handling in Rats with Chronic Myocardial Infarction
  • Binding, Partial Agonism, and Potentiation of α1-Adrenergic Receptor Function by Benzodiazepines: A Potential Site of Allosteric Modulation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics